Your session is about to expire
← Back to Search
Pembrolizumab for Multiple Myeloma (DREAMM 4 Trial)
DREAMM 4 Trial Summary
This trial is testing a new drug to treat multiple myeloma that has come back or does not respond to other treatments. The new drug will be given with another drug that is already used to treat this disease. The trial will see if the new drug is safe and works well with the other drug.
- Multiple Myeloma
DREAMM 4 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183DREAMM 4 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the standard applications for Pembrolizumab?
"Unresectable melanoma is a type of cancer that can be effectively managed with pembrolizumab. Additionally, this medication can also help patients with microsatellite instability high, those at high risk of recurrence, and other disease states."
How many people are recruited for this experiment?
"This study is not looking for new participants at the moment. The trial was first advertised on March 14th, 2019 and updated as recently as May 11th, 2022. Currently, there are 827 other trials related to multiple myeloma and 1032 trials concerning Pembrolizumab that are searching for volunteers."
What are the goals of this research?
"According to the sponsor, GlaxoSmithKline, the primary outcome for this trial will be Part 1: The number of patients with abnormal hematology readings. This objective will be evaluated over a two-year period. Additionally, investigators will also be looking at secondary outcomes including Part 2:maximum concentration in blood plasma following administration of GSK2857916 intravenously in combination with pembrolizumab after the first dose., Part 2: time until best response is observed (as defined as the time between date of first dose and first best documented response among subjects who achieved a confirmed response of PR or better), and Part"
What are some similar investigations that have utilized Pembrolizumab?
"First studied in 2010 at City of Hope, pembrolizumab has completed 251 clinical trials with approximately 1032 active studies. A large number of these investigations are being conducted out of Charlotte, North carolina."
Is this clinical trial being administered in multiple states?
"Presently, this experiment is being conducted in Charlotte, Indianapolis and Toronto; as well as 6 other cities. To cut down on travel time and costs, select the site that is geographically closest to you."
Are new enrollees still being accepted for this experiment?
"Currently, this clinical trial is not recruiting patients. The study was first posted on 3/14/2019 and updated for the last time on 5/11/2022. There are 827 other trials actively looking for candidates with multiple myeloma and 1032 trials involving Pembrolizumab that are currently admitting patients."
Share this study with friends
Copy Link
Messenger